Expiration date: September 8, 2014
Contact: Suzanne Forry-Schaudies, Ph.D.
(301) 435-9147, email@example.com
The NCI is particularly interested in validated hits for targets that address unmet needs in the prevention, treatment, or diagnosis of cancer. Strategies that include testing of in vivo chemical probe activity in primary human tumor cells are encouraged. In vivo chemical probes may be appropriate for entry in the NCI Experimental Therapeutics (NExT) Program for further development to clinical candidate status and testing in clinical trials. See http://next.cancer.gov/ for the NExT application process. Applicants may also find the NCI Developmental Therapeutics Program (http://dtp.nci.nih.gov ) resources to be helpful.